Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027

2.1 AIS Market Forecast to Reach $10.6B by 2027
2.2 The AIS Late-Stage Pipeline Focus on Improving Stroke Outcome
2.3 Current Treatments Leave High Level of Unmet Need in the AIS Market
2.4 Opportunities Will Remain for New Entrants
2.5 Late-Stage Pipeline Drugs Entering the AIS Market Will Be a Key Driver of Growth
2.6 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for AIS (2017-2027)
5.5.1 First-Ever Diagnosed Incident Cases of AIS
5.5.1 Age-Specific First-Ever Diagnosed Incident Cases of AIS
5.5.2 Sex-Specific First-Ever Diagnosed Incident Cases of AIS
5.5.3 Recurrent Diagnosed Incident Cases of AIS
5.5.4 First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype
5.5.5 Diagnosed Prevalent Cases of AIS
5.5.6 Age-Specific Diagnosed Prevalent Cases of AIS
5.5.7 Sex-Specific Diagnosed Prevalent Cases of AIS
5.5.8 AIS Mortality
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6.1 Diagnosis and Treatment Overview
6.1.1 AIS
6.1.2 TIA
6.2 Treatment Guidelines
6.3 US
6.4 5EU
6.5 Japan
6.6 China

7.1 Overview

8.1 Overview
8.2 Safer and More Effective Thrombolysis
8.3 Effective Therapies to Improve Clinical Outcome
8.4 Long-Term Compliance with Secondary Stroke Prevention Therapies
8.5 Access to Rapid Diagnosis and Acute Treatment

9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 Neuroprotective Agents
9.2.2 Stem Cell Therapies

10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Roche Portfolio Assessment
10.4 Boehringer Ingelheim Portfolio Assessment
10.5 Bristol-Myers Squibb Portfolio Assessment
10.6 Janssen Portfolio Assessment
10.7 Daiichi Sankyo Portfolio Assessment
10.8 AstraZeneca Portfolio Assessment
10.9 ZZ Biotech Portfolio Assessment
10.10 NoNO Inc. Portfolio Assessment
10.11 Biogen Portfolio Assessment
10.12 Athersys Portfolio Assessment
10.13 SanBio Portfolio Assessment

11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers

12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs Interviewed for This Report
12.4.1 KOLs
12.4.2 Primary Research - Prescriber Survey
12.5 About the Authors
12.5.1 Analyst
12.5.2 Therapy Area Director
12.5.3 Epidemiologist
12.5.4 Managing Epidemiologist
12.5.5 Global Director of Therapy Analysis and Epidemiology
12.5.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 Contact Us
12.8 Disclaimer

Table 1: AIS: Key Metrics in the 8MM
Table 2: TOAST Classification of Subtypes of AIS
Table 3: Risk Factors and Comorbidities for AIS
Table 4: Evaluation of Patients with Suspected Acute Ischemic Stroke or Transient Ischemic Attack
Table 5: Criteria for Thrombolysis Using Activase in Patients with AIS
Table 6: ABCD2 Score Used for Risk of Stroke Assessment
Table 7: Treatment Guidelines for AIS and TIA
Table 8: Country Profile - US
Table 9: Country Profile - 5EU
Table 10: Country Profile - Japan
Table 11: Country Profile - China
Table 12: Leading Treatments for AIS and TIA, 2018
Table 13: Roche’s AIS/TIA Portfolio Assessment, 2018
Table 14: Boehringer Ingelheim’s AIS Portfolio Assessment, 2018
Table 15: Bristol-Myers Squibb’s AIS Portfolio Assessment, 2018
Table 16: Janssen’s AIS Portfolio Assessment, 2018
Table 17: Daiichi Sankyo’s AIS Portfolio Assessment, 2018
Table 18: AstraZeneca’s AIS Portfolio Assessment, 2018
Table 19: ZZ Biotech’s AIS Portfolio Assessment, 2018
Table 20: NoNO Inc.’s AIS Portfolio Assessment, 2018
Table 21: Biogen’s AIS Portfolio Assessment, 2018
Table 22: Athersys’ AIS Portfolio Assessment, 2018
Table 23: SanBio’s AIS Portfolio Assessment, 2018
Table 24: AIS Market - Global Drivers and Barriers, 2017-2027
Table 25: Key Events Impacting Sales for AIS and TIA in the US, 2017-2027
Table 26: AIS Market - Drivers and Barriers in the US, 2017-2027
Table 27: Key Events Impacting Sales for AIS in the 5EU, 2017-2027
Table 28: AIS Market - Drivers and Barriers in the 5EU, 2017-2027
Table 29: Key Events Impacting Sales for AIS in Japan, 2017-2027
Table 30: AIS Market - Global Drivers and Barriers in Japan, 2017-2027
Table 31: Key Events Impacting Sales for AIS in China, 2017-2027
Table 32: AIS Market - Global Drivers and Barriers in China, 2017-2027
Table 33: Key Historical and Projected Launch Dates for AIS
Table 34: Key Historical and Projected Patent Expiry Dates for AIS
Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

Figure 1: Global Sales Forecast by Country for AIS in 2017 and 2027
Figure 2: Analysis of the Company Portfolio Gap in AIS During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That Are Expected to Be Licensed for the Treatment of AIS During the Forecast Period
Figure 4: Main Types and Processes of Acute Ischemic Stroke (AIS) and Its Management
Figure 5: Stroke-Induced Neuronal Cell Death and Therapeutic Targets of Pipeline Candidates
Figure 6: 8MM, Age-Standardized First-Ever Diagnosed Incidence of AIS, Men, Ages =18 Years, 2007-2027
Figure 7: 8MM, Age-Standardized First-Ever Diagnosed Incidence of AIS, Women, Ages =18 Years, 2007-2027
Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of AIS, Men, Ages =18 Years, 2007-2027
Figure 9: 8MM, Age-Standardized Diagnosed Prevalence of AIS, Women, Ages =18 Years, 2007-2027
Figure 10: Sources Used and Not Used for First-Ever Diagnosed Incident Cases of AIS
Figure 11: Sources Used and Not Used for Recurrent Diagnosed Incident Cases of AIS
Figure 12: Sources Used and Not Used for First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype
Figure 13: Sources Used and Not Used for Diagnosed Prevalent Cases of AIS
Figure 14: Sources Used and Not Used for AIS Mortality
Figure 15: 8MM, First-Ever Diagnosed Incident Cases of AIS, Men and Women, Ages =18 Years, 2017
Figure 16: 8MM, Age-Specific First-Ever Diagnosed Incident Cases of AIS, Men and Women, 2017
Figure 17: 8MM, Sex-Specific First-Ever Diagnosed Incident Cases of AIS, Ages =18 Years, 2017
Figure 18: 8MM, Recurrent Diagnosed Incident Cases of AIS, Ages =18 Years, Men and Women, 2017
Figure 19: 8MM, First-Ever Diagnosed Incident Cases of AIS by TOAST Subtype, Ages =18 Years, Men and Women, 2017
Figure 20: 8MM, Diagnosed Prevalent Cases of AIS, Men and Women, Ages =18 Years, 2017
Figure 21: 8MM, Age-Specific Diagnosed Prevalent Cases of AIS, Men and Women, 2017
Figure 22: 8MM, Sex-Specific Diagnosed Prevalent Cases of AIS, Ages =18 Years, 2017
Figure 23: 8MM, AIS Mortality, Ages =18 Years, Men and Women, 2017-2027
Figure 24: Acute Ischemic Stroke Management
Figure 25: Transient Ischemic Attack Management
Figure 26: Unmet Needs and Opportunities in AIS and TIA
Figure 27: Overview of the Development Pipeline in AIS and TIA
Figure 28: Key Phase II/III Trials for the Promising Pipeline Agents That Are Expected to Be Licensed for AIS or TIA or Both in the 8MM During the Forecast Period
Figure 29: Competitive Assessment of the Late-Stage Pipeline Agents That Are Expected to Be Licensed for the Treatment of AIS During the Forecast Period
Figure 30: Analysis of the Company Portfolio Gap in AIS and TIA During the Forecast Period
Figure 31: Global (8MM) Sales Forecast by Country for AIS and TIA Combined in 2017 and 2027
Figure 32: Sales Forecast by Class for AIS and TIA Combined in the US in 2017 and 2027
Figure 33: Sales Forecast by Class for AIS and TIA Combined in the 5EU in 2017 and 2027
Figure 34: Sales Forecast by Class for AIS and TIA Combined in Japan in 2017 and 2027
Figure 35: Sales Forecast by Class for AIS and TIA Combined in China in 2017 and 2027